22 results
Pain Assessment and Management Initiative (PAMI) - Neuropathic Pain Medications:

Agent, Initiation Dose and Max Dosages

 -
Assessment and Management ... Initiative (PAMI ... Agent, Initiation Dose ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Transdermal Medications

#Management #Pain #Pharmacology #Transdermal #Topical #Medications #Doses #Dosing
Assessment and Management ... Initiative (PAMI ... #Management # ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Assessment and Management ... Initiative (PAMI ... NonOpioid #Analgesics #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Muscle Relaxants - Agents and Dosing

#Management #Pain #Pharmacology #Muscle
Assessment and Management ... Initiative (PAMI ... Relaxers #Relaxants #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Nerve Blocks - Nerve Distribution, Agents and Dosing Table
Assessment and Management ... Initiative (PAMI ... Nerve #Blocks #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Intranasal and Nebulized Medications- Agents and Dosing

#Management #Pain #Pharmacology
Assessment and Management ... Initiative (PAMI ... and Nebulized Medications ... #Doses #Dosing ... #Table #PAMI
Oral anti-hypertensives with relative fast onset of action (Hypertensive Emergency)

The key concern with oral antihypertensive agents
(e.g. procedural ... of medication to ... you escalate the dose ... Hypertensive #Emergency #Management ... #Pharmacology #Table
Assessment of the Child with Eczema
Distribution of atopic eczema - The distribution of eczema tends to
- Bacterial infection ... - Viral infection ... or reduction in medication ... allergens, irritants, medications ... condition and its management
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Achieve a total dose ... achieve total dose ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Tocilizumab 4-8mg/kg ... respiratory tract infection ... Siltuximab 11mg/kg ... #Pharmacology #Management ... #Medications